Cable news and COVID-19 vaccine uptake.

COVID-19 vaccines have reduced infections and hospitalizations across the globe, yet resistance to vaccination remains strong. This paper investigates the role of cable television news in vaccine hesitancy and associated local vaccination rates in the United States. We find that, in the earlier stages of the vaccine roll-out (starting May 2021), higher local viewership of Fox News Channel has been associated with lower local vaccination rates. We can verify that this association is causal using exogenous geographical variation in the channel lineup. The effect is driven by younger individuals (under 65 years of age), for whom COVID-19 has a low mortality risk. Consistent with changes in beliefs about the effectiveness of the vaccine as a mechanism, we find that Fox News increased reported vaccine hesitancy in local survey responses. We can rule out that the effect is due to differences in partisanship, to local health policies, or to local COVID-19 infections or death rates. The other two major television networks, CNN and MSNBC, have no effect. That, in turn, indicates that more differentiated characteristics, like the networks' messaging or tendency for controversy, matter and that the effect of Fox News on COVID-19 vaccine uptake is not due to the general consumption of cable news. We also show that there is no historical effect of Fox News on flu vaccination rates, suggesting that the effect is COVID-19-specific and not driven by general skepticism toward vaccines.

Complete reversibility of pembrolizumab-induced eosinophilic fasciitis without corticosteroids: A case report.

Checkpoint inhibitor immunotherapy has recently started to play a fundamental role in the management of metastatic melanoma. It is however accountable for many undesirable adverse effects involving many organ systems. Eosinophilic fasciitis is a rare immune-related adverse effect associated to checkpoint inhibitors such as pembrolizumab and nivolumab. We report the case of a 25-year-old male who received pembrolizumab as a second-line therapy for metastatic melanoma. Approximately 8 months after starting the treatment, the patient developed signs and symptoms of eosinophilic fasciitis, including edema of his hands and lower legs, as well as joint limitation. Pembrolizumab was discontinued after 15 cycles because of symptom progression. The patient experienced complete resolution of symptoms 4 months after cessation of pembrolizumab and without corticosteroids. This case illustrates the reversibility of this immune adverse effect by discontinuation of the treatment, speculating that corticotherapy may not be needed in all cases.